U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Drusen

MedGen UID:
488956
Concept ID:
C1260959
Disease or Syndrome; Finding
Synonym: Subretinal Extracellular Matrix Deposit
SNOMED CT: Drusen (18695008)
 
HPO: HP:0011510

Definition

Drusen (singular, 'druse') are tiny yellow or white accumulations of extracellular material (lipofuscin) that build up in Bruch's membrane of the eye. [from HPO]

Conditions with this feature

North Carolina macular dystrophy
MedGen UID:
147590
Concept ID:
C0730294
Disease or Syndrome
North Carolina macular dystrophy (NCMD, MCDR1) is a congenital autosomal dominant trait that appears to be completely penetrant. It is generally nonprogressive. The ophthalmoscopic findings are highly variable and are always much more dramatic than one would predict from the relatively good visual acuity level, which ranges from 20/20 to 20/400 (median, 20/60). Patients may have only a few drusen in the central macular region (grade I), confluent drusen confined to the central macular region (grade II), or a severe macular coloboma/staphyloma (grade III) involving 3 to 4 disc areas of the central macular region. Choroidal neovascular membranes develop in some patients. Color vision is normal. Electrophysiologic studies are also normal (summary by Small, 1998). Genetic Heterogeneity of Retinal Macular Dystrophy MCDR2 (608051) is caused by mutation in the PROM1 gene (604365) on chromosome 4p15. MCDR3 (608850) is caused by a duplication on chromosome 5p15. MCDR4 (619977) is caused by mutation in the CLEC3B gene (187520) on chromosome 3p21. MCDR5 (see 613660) is caused by mutation in the CDHR1 gene (609502) on chromosome 10q23. See MAPPING for possible additional loci for MCDR.
Basal laminar drusen
MedGen UID:
152676
Concept ID:
C0730295
Disease or Syndrome
Drusen are extracellular deposits that accumulate below the retinal pigment epithelium on Bruch membrane. They appear as slightly raised, yellow subretinal nodules randomly scattered in the macula. 'Drusen' is the plural for 'Druse,' German for 'nodule' or 'crystal' (summary by Bok, 2002, Boon et al., 2008).
Patterned macular dystrophy 2
MedGen UID:
332348
Concept ID:
C1837029
Disease or Syndrome
Butterfly-shaped pigmentary macular dystrophy is an autosomal dominant eye disease characterized by bilateral accumulation of pigment in the macular area that resembles the wings of a butterfly (summary by van Lith-Verhoeven et al., 2003). For a general phenotypic description and a discussion of genetic heterogeneity of patterned macular dystrophy, see 169150.
Macular degeneration, age-related, 3
MedGen UID:
373276
Concept ID:
C1837187
Disease or Syndrome
Age-related macular degeneration-3 (ARMD3) is characterized by numerous small round yellow lesions visible at the temporal edge of the macula. Larger, less distinct yellow areas near the center of the macula are also observed, which represent areas of pigment epithelial detachment (Stone et al., 2004). For a phenotypic description and a discussion of genetic heterogeneity of age-related macular degeneration, see 603075.
Adult-onset foveomacular vitelliform dystrophy
MedGen UID:
334280
Concept ID:
C1842914
Disease or Syndrome
Adult-onset foveomacular vitelliform dystrophy, also known as adult vitelliform macular dystrophy, adult-type foveomacular dystrophy, adult vitelliform macular degeneration, pseudovitelliform macular degeneration, and adult-onset foveomacular pigment epithelial dystrophy, is characterized by a solitary, oval, slightly elevated yellowish subretinal lesion of the fovea that is similar in appearance to the vitelliform or egg-yolk stage of Best disease (153700). Initially the yellow lesion may be present in only one eye. The size is generally one-third to one disc diameter, and small yellow flecks are seen in the paracentral lesion. Patients usually become symptomatic in the fourth or fifth decade of life with a protracted decrease of visual acuity and mild metamorphopsia. Electrooculographic testing reveals a normal or only slightly reduced Arden ratio, which is intensely abnormal in Best disease. The prognosis is optimistic, as most patients retain reading vision throughout life (Felbor et al., 1997; Yamaguchi et al., 2001). For a discussion of genetic heterogeneity of vitelliform macular dystrophy, see VMD1 (153840).
Retinal dystrophy, reticular pigmentary, of posterior pole
MedGen UID:
341448
Concept ID:
C1849407
Disease or Syndrome
Reticular pigmentary retinal dystrophy is a form of patterned dystrophy (see MDPT1, 169150) characterized by a reticular pattern of pigmentation that likely appears in infancy and may be fully developed at age 15 years. Indirect funduscopy has shown that the condition is bilateral and symmetric and that the pigmentary deposits are localized below the neuroepithelium, very likely in the pigment epithelium. The reticulum extends from the macula in all directions, sparing the midperiphery and periphery. Visual acuity is unaffected or only minimally affected in advanced stages. Retinal function testing is normal, although the electrooculogram and dark adaptation can be at the lower limit of normal values (summary by Schauwvlieghe et al., 2013).
Choroidal dystrophy, central areolar, 3
MedGen UID:
442631
Concept ID:
C2751055
Disease or Syndrome
Age related macular degeneration 13
MedGen UID:
815853
Concept ID:
C3809523
Disease or Syndrome
Age-related macular degeneration (ARMD) is a multifactorial disorder of the central retina that is the most prevalent cause of progressive vision loss in the developed world. As in other chronic age-related diseases, most cases result from interplay between multiple environmental and genetic factors, with a resultant spectrum of phenotypes. In rare cases, ARMD may manifest early, but there is an exponential rise in prevalence after the age of 60 years (summary by Pras et al., 2015). For a phenotypic description and a discussion of genetic heterogeneity of age-related macular degeneration (ARMD), see 603075.
Vitelliform macular dystrophy 4
MedGen UID:
863779
Concept ID:
C4015342
Disease or Syndrome
Macular dystrophies are inherited retinal dystrophies in which various forms of deposits, pigmentary changes, and atrophic lesions are observed in the macula lutea, the cone-rich region of the central retina. Vitelliform macular dystrophies (VMDs) form a subset of macular dystrophies characterized by round yellow deposits, usually at the center of the macula and containing lipofuscin, a chemically heterogeneous pigment visualized by autofluorescence imaging of the fundus (summary by Manes et al., 2013). Vitelliform macular dystrophy-4 (VMD4) is characterized by late-onset moderate visual impairment, small satellite drusen-like lesions in the foveal area, preservation of retinal pigment epithelium (RPE) reflectivity, deposits above the RPE between the ellipsoid and outer segment interdigitation lines on spectral-domain optical coherence tomography (SD-OCT), and normal or borderline results on electrooculography (EOG) (Meunier et al., 2014). In most families with VMD4 caused by compound heterozygous or homozygous mutations in IMPG1, asymptomatic heterozygous carriers have been found to have fundus changes (Manes et al., 2013; Brandl et al., 2017). Brandl et al. (2017) examined patients with VMD4, caused by mutation in the IMPG1 gene, and patients with VMD5 (616152), caused by mutation in the IMPG2 gene, and observed strikingly similar phenotypic characteristics. They noted that retinal lesions progressed in consecutive stages, with the initial development of a single vitelliform lesion in the central macula, with detachment of the neurosensory retina and hyperreflective material located above a preserved Bruch membrane/RPE on SD-OCT. Next, resorption of the hyperreflective material occurs, leaving behind a dome-shaped, optically empty cavity; alternatively, the foveal cavity formed by retinal detachment may become successively filled with material. Finally, there is collapse of the cavity with central retinal atrophy and loss of RPE, resulting in the most pronounced loss of visual acuity. The authors also noted that symptoms tended to be more severe in patients with IMPG1 mutations. For a discussion of genetic heterogeneity of vitelliform macular dystrophy, see VMD1 (153840).
Usher syndrome, type 1M
MedGen UID:
1684669
Concept ID:
C5231434
Disease or Syndrome
Usher syndrome type 1M (USH1M) is characterized by prelingual sensorineural hearing loss, vestibular dysfunction, and retinitis pigmentosa (Ahmed et al., 2018). For a general phenotypic description and discussion of genetic heterogeneity of Usher syndrome, see USH1 (276900).

Professional guidelines

PubMed

Shome I, Thathapudi NC, Aramati BMR, Kowtharapu BS, Jangamreddy JR
Int Ophthalmol 2023 Oct;43(10):3891-3909. Epub 2023 Jun 22 doi: 10.1007/s10792-023-02767-2. PMID: 37347455
Sibony PA, Kupersmith MJ, Kardon RH
J Neuroophthalmol 2021 Mar 1;41(1):77-92. doi: 10.1097/WNO.0000000000001078. PMID: 32909979Free PMC Article
Margolin E
Pract Neurol 2019 Aug;19(4):302-309. Epub 2019 Jun 13 doi: 10.1136/practneurol-2018-002057. PMID: 31196885

Recent clinical studies

Etiology

Mack HG, Colville DJ, Harraka P, Savige JA, Invernizzi A, Fraser-Bell S
Clin Exp Optom 2022 Jul;105(5):474-486. Epub 2021 Dec 8 doi: 10.1080/08164622.2021.2003691. PMID: 34877922
Keenan TDL, Cukras CA, Chew EY
Adv Exp Med Biol 2021;1256:1-31. doi: 10.1007/978-3-030-66014-7_1. PMID: 33847996
Gheorghe A, Mahdi L, Musat O
Rom J Ophthalmol 2015 Apr-Jun;59(2):74-7. PMID: 26978865Free PMC Article
Crabb JW
Cold Spring Harb Perspect Med 2014 May 5;4(7):a017194. doi: 10.1101/cshperspect.a017194. PMID: 24799364Free PMC Article
De Laey JJ
Bull Soc Belge Ophtalmol 1993;249:11-22. PMID: 7952338

Diagnosis

Venkatakrishnan P, Sreenivasan J, Chenthilnathan C
Indian J Ophthalmol 2023 Aug;71(8):2937. doi: 10.4103/IJO.IJO_3019_22. PMID: 37530259Free PMC Article
Margolin E
Pract Neurol 2019 Aug;19(4):302-309. Epub 2019 Jun 13 doi: 10.1136/practneurol-2018-002057. PMID: 31196885
Spaide RF, Ooto S, Curcio CA
Surv Ophthalmol 2018 Nov-Dec;63(6):782-815. Epub 2018 May 31 doi: 10.1016/j.survophthal.2018.05.005. PMID: 29859199
Gheorghe A, Mahdi L, Musat O
Rom J Ophthalmol 2015 Apr-Jun;59(2):74-7. PMID: 26978865Free PMC Article
De Laey JJ
Bull Soc Belge Ophtalmol 1993;249:11-22. PMID: 7952338

Therapy

Heloterä H, Kaarniranta K
Cells 2022 Nov 1;11(21) doi: 10.3390/cells11213453. PMID: 36359849Free PMC Article
Nashine S
Cells 2021 Sep 19;10(9) doi: 10.3390/cells10092483. PMID: 34572131Free PMC Article
Kjeldsen EW, Nordestgaard LT, Frikke-Schmidt R
Int J Mol Sci 2021 Apr 27;22(9) doi: 10.3390/ijms22094547. PMID: 33925284Free PMC Article
Rahman N, Georgiou M, Khan KN, Michaelides M
Br J Ophthalmol 2020 Apr;104(4):451-460. Epub 2019 Nov 8 doi: 10.1136/bjophthalmol-2019-315086. PMID: 31704701Free PMC Article
Nowak JZ
Pharmacol Rep 2006 May-Jun;58(3):353-63. PMID: 16845209

Prognosis

Sacconi R, Fazzari G, Capuano V, Menean M, Beretta F, El Matri K, Bandello F, Souied E, Querques G
Ophthalmol Retina 2024 Nov;8(11):1066-1073. Epub 2024 Jun 4 doi: 10.1016/j.oret.2024.05.020. PMID: 38844200
Keenan TDL, Cukras CA, Chew EY
Adv Exp Med Biol 2021;1256:1-31. doi: 10.1007/978-3-030-66014-7_1. PMID: 33847996
Waldstein SM, Vogl WD, Bogunovic H, Sadeghipour A, Riedl S, Schmidt-Erfurth U
JAMA Ophthalmol 2020 Jul 1;138(7):740-747. doi: 10.1001/jamaophthalmol.2020.1376. PMID: 32379287Free PMC Article
Mitchell P, Liew G, Gopinath B, Wong TY
Lancet 2018 Sep 29;392(10153):1147-1159. doi: 10.1016/S0140-6736(18)31550-2. PMID: 30303083
Age-Related Eye Disease Study Research Group
Arch Ophthalmol 2001 Oct;119(10):1417-36. doi: 10.1001/archopht.119.10.1417. PMID: 11594942Free PMC Article

Clinical prediction guides

Keenan TDL, Cukras CA, Chew EY
Adv Exp Med Biol 2021;1256:1-31. doi: 10.1007/978-3-030-66014-7_1. PMID: 33847996
Agrón E, Mares J, Clemons TE, Swaroop A, Chew EY, Keenan TDL; AREDS and AREDS2 Research Groups
Ophthalmology 2021 Mar;128(3):425-442. Epub 2020 Aug 25 doi: 10.1016/j.ophtha.2020.08.018. PMID: 32858063Free PMC Article
Waldstein SM, Vogl WD, Bogunovic H, Sadeghipour A, Riedl S, Schmidt-Erfurth U
JAMA Ophthalmol 2020 Jul 1;138(7):740-747. doi: 10.1001/jamaophthalmol.2020.1376. PMID: 32379287Free PMC Article
Markowitz SN, Devenyi RG, Munk MR, Croissant CL, Tedford SE, Rückert R, Walker MG, Patino BE, Chen L, Nido M, Tedford CE
Retina 2020 Aug;40(8):1471-1482. doi: 10.1097/IAE.0000000000002632. PMID: 31404033Free PMC Article
Ferris FL 3rd, Wilkinson CP, Bird A, Chakravarthy U, Chew E, Csaky K, Sadda SR; Beckman Initiative for Macular Research Classification Committee
Ophthalmology 2013 Apr;120(4):844-51. Epub 2013 Jan 16 doi: 10.1016/j.ophtha.2012.10.036. PMID: 23332590Free PMC Article

Recent systematic reviews

Akpinar MH, Sengur A, Faust O, Tong L, Molinari F, Acharya UR
Comput Methods Programs Biomed 2024 Sep;254:108253. Epub 2024 May 28 doi: 10.1016/j.cmpb.2024.108253. PMID: 38861878
Mukriyani H, Malmqvist L, Subhi Y, Hamann S
Acta Ophthalmol 2024 Feb;102(1):15-24. Epub 2023 May 5 doi: 10.1111/aos.15690. PMID: 37144704
Allegrini D, Pagano L, Ferrara M, Borgia A, Sorrentino T, Montesano G, Angi M, Romano MR
Int Ophthalmol 2020 Aug;40(8):2119-2127. Epub 2020 May 7 doi: 10.1007/s10792-020-01365-w. PMID: 32383130
Gheorghe A, Mahdi L, Musat O
Rom J Ophthalmol 2015 Apr-Jun;59(2):74-7. PMID: 26978865Free PMC Article
Arnold JJ, Heriot W
BMJ Clin Evid 2007 Apr 1;2007 PMID: 19454069Free PMC Article

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...